Apparent mineralocorticoid excess

Trends in Endocrinology and Metabolism

Volumn 12, Issue 3, 2001, Pages 104-111

  Wilson, Robert C ^a   Nimkarn, Saroj ^a   New, Maria I ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; HSD11B2 PROTEIN, HUMAN; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASE;

CONSANGUINITY; FEMALE; GENETICS; HUMAN; HYPERTENSION; MALE; METABOLISM; MUTATION; PEDIGREE; REVIEW; SYNDROME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; CONSANGUINITY; CORTISONE; FEMALE; HUMANS; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASES; HYPERTENSION; MALE; MUTATION; PEDIGREE; SYNDROME;

EID: 0035319657     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00356-8     Document Type: Review

References (81)

1. Werder, E.A. et al. (1974) Unusual steroid excretion in a child with low-renin hypertension. Res. Steroids 6, 385-389
2. New, M.I. et al. (1977) Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J. Clin. Endocrinol. Metab. 44, 924-933
3. Ulick, S. et al. (1977) An abnormality in steroid reductive metabolism in a hypertensive syndrome. J. Clin. Endocrinol. Metab. 44, 799-802
4. Ulick, S. et al. (1979) Asyndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of Cortisol. J. Clin. Endocrinol. Metab. 49, 757-764
5. New, M.I. et al. (1982) Agenetic defect in Cortisol metabolism as the basis for the syndrome of apparent mineralocorticoid excess. In Endocrinology of Hypertension, Serono Symposia No. 50(Mantero, F. et al., eds), pp. 85-101, Academic Press
6. Oberfield, S.E. et al. (1983) Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 56, 332-339
7. Marver, D. et al. (1974) Renal aldosterone receptors: studies with (3H) aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc. Natl. Acad. Sci. U. S. A. 71, 1431-1435
8. Krozowski, Z.S. and Funder, J.W. (1983) Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc. Natl. Acad. Sci. U. S. A. 80, 6056-6060
9. Arriza, J.L. et al. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237, 268-275
10. Funder, J.W. et al. (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242, 583-585
11. Stewart, P.M. et al. (1987) Mineralocorticoid activity of liquorice: 11-β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet ii, 821-824
12. Farese, R.V., Jr et al. (1991) Licorice-induced hypermineralocorticoidism. New Engl. J. Med. 325, 1223-1227
13. Stewart, P.M. et al. (1990) Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 β-hydroxysteroid dehydrogenase activity in man. Clin. Sci. 78, 49-54
14. Lakshmi, V. and Monder, C. (1988) Purification and characterization of the corticosteroid 11 betadehydrogenase component of the rat liver 11 β-hydroxysteroid dehydrogenase complex. Endocrinology 123, 2390-2398
15. Tannin, G.M. et al. (1991) The human gene for 11 β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J. Biol. Chem. 266, 16653-16658
16. Albiston, A.L. et al. (1994) Cloning and tissue distribution of the human 11 β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105, R11-R17
17. Nikkila, H. et al. (1993) Defects in the HSD11 gene encoding 11 β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J. Clin. Endocrinol. Metab. 77, 687-691
18. Rusvai, E. and Naray-Fejes-Toth, A. (1993) A new isoform of 11 β-hydroxysteroid dehydrogenase in aldosterone target cells. J. Biol. Chem. 268, 10717-10720
19. Agarwal, A.K. et al. (1994) NAD(+)-dependent isoform of 11 β-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney J. Biol. Chem. 269, 25959-25962
20. Naray-Fejes-Toth, A. and Fejes-Toth, G. (1995) Expression cloning of the aldosterone target cell-specific 11 β-hydroxysteroid dehydrogenase from rabbit collecting duct cells. Endocrinology 136, 2579-2586
21. Whorwood, C.B. et al. (1995) Detection of human 11β-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform in renal collecting ducts. Mol. Cell. Endocrinol. 110, R7-R11
22. White, P.C. et al. (1997) 11 β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 18, 135-156
23. Krozowski, Z.S. et al. (1995) Localization of the gene for human 11β-hydroxysteroid dehydrogenase type 2 enzyme to chromosome 16q22. Cytogenet. Cell Genet. 71, 124-125
24. Agarwal, A.K. et al. (1995) Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11β-hydroxysteroid dehydrogenase. Genomics 29, 195-199
25. Brown, R.W. et al. (1993) Human placental 11 β-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 132, 2614-2621
26. Whorwood, C.B. et al. (1994) Epithelial cell localization of type 2 11 β-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology 135, 2533-2541
27. Stewart, P.M. et al. (1996) Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 347, 88-91
28. Kitanaka, S. et al. (1997) A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 82, 4054-4058
29. Li, A. et al. (1997) Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J. Hypertens. 15, 1397-1402
30. Wilson, R.C. et al. (1995) Amutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80, 2263-2266
31. Mune, T. et al. (1995) Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat. Genet. 10, 394-399
32. Wilson, R.C. et al. (1995) Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80, 3145-3150
33. Dave-Sharma, S. et al. (1998) Extensive personal experience: examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 83, 2244-2254
34. Wilson, R.C. et al. (1998) Agenetic defect resulting in mild low-renin hypertension. Proc. Natl. Acad. Sci. U. S. A. 95, 10200-10205
35. LI, A. et al. (1998) Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess. Am. J. Hum. Genet. 63, 370-379
36. Hellman, L. et al. (1971) Renal capture and oxidation of Cortisol in man. J. Clin. Endocrinol. Metab. 33, 52-62
37. Monder, C. et al. (1986) The syndrome of apparent mineralocorticoid excess: its association with 11 β-dehydrogenase and 5 β-reductase deficiency and some consequences for corticosteroid metabolism. J. Clin. Endocrinol. Metab. 63, 550-557
38. Morineau, G. et al. (1999) Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11βHSD2 causing apparent mineralocorticoid excess. Hypertension 34, 435-441
39. Shackleton, C.H. et al. (1985) Congenital 11 β-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clin. Endocrinol. 22, 701-712
40. Stewart, P.M. et al. (1988) Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J. Clin. Invest. 82, 340-349
41. Batista, M.C. et al. (1986) Spironolactone-reversible rickets associated with 11 β-hydroxysteroid dehydrogenase deficiency syndrome. J. Pediatr. 109, 989-993
42. Kitanaka, S. et al. (1996) Apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Clin. Endocrinol. 44, 353-359
43. Sann, L. et al. (1976) Unusual low plasma renin hypertension in a child. J. Clin. Endocrinol. Metab. 43, 265-271
44. Shackleton, C.H. et al. (1980) Hypertension in a four-year-old child: gas Chromatographic and mass spectrometric evidence for deficient hepatic metabolism of steroids. J. Clin. Endocrinol. Metab. 50, 786-802
45. Honour, J.W. et al. (1983) Fatal, low renin hypertension associated with a disturbance of cortisol metabolism. Arch. Dis. Child. 58, 1018-1020
46. Milford, D.V. et al. (1995) Mineralocorticoid hypertension and congenital deficiency of 11β-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess. Clin. Endocrinol. 43, 241-246
47. Muller-Berghaus, J. et al. (1996) Diagnosis and treatment of a child with the syndrome of apparent mineralocorticoid excess type 1. Acta Paediatr. 85, 111-113
48. Fiselier, T.J. et al. (1982) Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child. Horm. Res. 16, 107-114
49. Harinck, H.I. et al. (1984) Apparent mineralocorticoid excess and deficient 11 β-oxidation of cortisol in a young female. Clin. Endocrinol. 21, 505-514
50. Winter, J.S.D. and McKenzie, J.K. (1977) A syndrome of low-renin hypertension in children. In Juvenile Hypertension (New, M.I. and Levine, S.,eds), pp. 123-132, Raven Press
51. Gourmelen.M. et al. (1996) 11 β-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial hypertension. Diagnosis and therapeutic approach in two young brothers. Eur. J. Endocrinol. 135, 238-244
52. Gomez-Sanchez, E.P et. al. (1995) The modulation of central control of blood pressure. Steroids 60, 69-72
53. Roberts, A.J. and Keith, L.D. (1995) Corticosteroids enhance convulsion susceptibility via central mineralocorticoid receptors. Psychoneuroendocrinology 20, 891-902
54. Gomez-Sanchez, EP. et al. (1996) Mineralocorticoids, salt and high blood pressure. Steroids 61, 184-188
55. Stewart, P.M. et al. (1995) Type2 11 β-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J. Clin. Endocrinol. Metab. 80, 885-890
56. Benediktsson, R. et al. (1995) 11β-Hydroxysteroid dehydrogenase activity in intact dually-perfused fresh human placenta predicts birth weight. J. Endocrinol. 144 (Suppl.), 166
57. Edwards, C.R. et al. (1996) 11 β-Hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects. Steroids 61, 263-269
58. Krozowski, Z. (1999) The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects. Mol. Cell. Endocrinol. 151, 121-127
59. Forest, M.G. et al. (1989) Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: update 88 of the French multicentric study. Endocr. Res. 15, 277-301
60. Forest, M.G. et al. (1993) Prenatal diagnosis and treatment of 21-hydroxylasedeficiency. J. Steroid Biochem. Mol. Biol. 45, 75-82
61. Mercado, A.B. et al. (1995) Extensive personal experience: prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 80, 2014-2020
62. Carlson, A.D. et al. (1999) Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J. Steroid Biochem. Mol. Biol. 69, 19-29
63. Obeyesekere, V.R. et al. (1995) The R337C mutation generates a high Km 11 β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80, 3381-3383
64. Ferrari, P et al. (1996) Point mutations abolish 11β-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol. Cell. Endocrinol. 119, 21-24
65. Ugrasbul, E et al. (1999) Prevalence of mild apparent mineralocorticoid excess in Mennonites. J. Clin. Endocrinol. Metab. 84, 4735-4738
66. Ulick, S. et al. (1990) Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 70, 200-206
67. Ulick, S. et al. (1992) Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 74, 593-599
68. Tedde, R. et al. (1992) Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess. J. Endocrinol. Invest. 15, 471-474
69. Mantero, E et al. (1994) Apparent mineralocorticoid excess type II. Steroids 59, 80-83
70. Palermo, M. et al. (1998) Cure of apparent mineralocorticoid excess by kidney transplantation. New Engl. J. Med. 339, 1787-1788
71. Soro, A. et al. (1995) Evidence of coexisting changes in 11 β-hydroxysteroid dehydrogenase and 5 β-reductase activity in subjects with untreated essential hypertension. Hypertension 25, 67-70
72. Takeda, Y. et al. (1996) Endogenous renal 11 β-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 27, 197-201
73. Walker, B. et al. (1998) Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 31, 891-895
74. Walker, B. et al. (1996) Increased vasoconstrictor nsitivity to glucocorticoids in essential hypertension. Hypertension27, 190-196
75. Weinberger, M. et al. (1986) Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 8, II127-II134
76. Weinberger, M. (1996) Salt sensitivity of blood pressure in humans. Hypertension 27, 481-490
77. Lovati, E. et al. (1999) Molecular basis of human salt sensitivity: the role of the 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Endocrinol. Metab. 84, 3745-3749
78. Watson, B., Jr et al. (1996) Genetic association of 11 β-hydroxysteroid dehydrogenase type 2 SD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 28, 478-482
79. Wedel, D.C. (1974) The Story of Alexanderwohl, Mennonite Press
80. Rogoff, D. et al. (1998) The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 83, 4391-4393
81. Ulick, S. et al. (1992) Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 74, 593-599